Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer.

Navidi M, Phillips AW, Griffin SM, Duffield KE, Greystoke A, Sumpter K, Sinclair RCF.

Br J Surg. 2018 Jun;105(7):900-906. doi: 10.1002/bjs.10802. Epub 2018 Mar 30.

PMID:
29601082
2.

Metastatic Brain Disease from Non-small Cell Lung Cancer - Getting Back to the Drawing Board.

Greystoke A, Mulvenna P.

Clin Oncol (R Coll Radiol). 2018 Mar;30(3):137-143. doi: 10.1016/j.clon.2017.12.020. Epub 2018 Jan 17. No abstract available.

PMID:
29352644
3.

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.

Vishwanathan K, Dickinson PA, Bui K, Cassier PA, Greystoke A, Lisbon E, Moreno V, So K, Thomas K, Weilert D, Yap TA, Plummer R.

J Clin Pharmacol. 2018 Apr;58(4):474-484. doi: 10.1002/jcph.1035. Epub 2017 Nov 26.

PMID:
29178442
4.

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.

Greystoke A, Steele N, Arkenau HT, Blackhall F, Md Haris N, Lindsay CR, Califano R, Voskoboynik M, Summers Y, So K, Ghiorghiu D, Dymond AW, Hossack S, Plummer R, Dean E.

Br J Cancer. 2017 Sep 26;117(7):938-946. doi: 10.1038/bjc.2017.271. Epub 2017 Aug 24.

5.

Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.

Bertranou E, Bodnar C, Dansk V, Greystoke A, Large S, Dyer M.

J Med Econ. 2018 Feb;21(2):113-121. doi: 10.1080/13696998.2017.1377718. Epub 2017 Sep 21.

PMID:
28880737
6.

Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.

Califano R, Greystoke A, Lal R, Thompson J, Popat S.

Lung Cancer. 2017 Sep;111:51-58. doi: 10.1016/j.lungcan.2017.06.004. Epub 2017 Jun 9. Review.

7.

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).

Cho BC, Kim DW, Bearz A, Laurie SA, McKeage M, Borra G, Park K, Kim SW, Ghosn M, Ardizzoni A, Maiello E, Greystoke A, Yu R, Osborne K, Gu W, Scott JW, Passos VQ, Lau YY, Wrona A.

J Thorac Oncol. 2017 Sep;12(9):1357-1367. doi: 10.1016/j.jtho.2017.07.005. Epub 2017 Jul 17.

8.

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TR, Anthoney A, Ranson M, Boddy AV, Plummer R.

Eur J Cancer. 2016 Nov;68:1-10. doi: 10.1016/j.ejca.2016.08.026. Epub 2016 Sep 28.

PMID:
27693888
9.

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.

Milojkovic Kerklaan B, Slater S, Flynn M, Greystoke A, Witteveen PO, Megui-Roelvink M, de Vos F, Dean E, Reyderman L, Ottesen L, Ranson M, Lolkema MP, Plummer R, Kristeleit R, Evans TR, Schellens JH.

Invest New Drugs. 2016 Jun;34(3):329-37. doi: 10.1007/s10637-016-0344-9. Epub 2016 Apr 2.

PMID:
27039386
10.

Development of a circulating miRNA assay to monitor tumor burden: From mouse to man.

Greystoke A, Ayub M, Rothwell DG, Morris D, Burt D, Hodgkinson CL, Morrow CJ, Smith N, Aung K, Valle J, Carter L, Blackhall F, Dive C, Brady G.

Mol Oncol. 2016 Feb;10(2):282-91. doi: 10.1016/j.molonc.2015.10.004. Epub 2015 Oct 28.

11.

Spindle cell carcinoma of the head and neck region: treatment and outcomes of 15 patients.

Iqbal MS, Paleri V, Brown J, Greystoke A, Dobrowsky W, Kelly C, Kovarik J.

Ecancermedicalscience. 2015 Nov 18;9:594. doi: 10.3332/ecancer.2015.594. eCollection 2015.

12.

The use of circulating biomarkers in early clinical trials in patients with cancer.

D'Arcangelo M, Margetts J, Greystoke A.

Biomark Med. 2015;9(10):1011-23. doi: 10.2217/bmm.15.51. Epub 2015 Oct 6. Review.

PMID:
26441037
13.

An introduction to stratified medicine.

Greystoke A, Chaturvedi A.

Drug Discov Today. 2015 Dec;20(12):1409-13. doi: 10.1016/j.drudis.2015.07.016. Epub 2015 Aug 4. No abstract available.

PMID:
26253659
14.

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

Basu B, Dean E, Puglisi M, Greystoke A, Ong M, Burke W, Cavallin M, Bigley G, Womack C, Harrington EA, Green S, Oelmann E, de Bono JS, Ranson M, Banerji U.

Clin Cancer Res. 2015 Aug 1;21(15):3412-9. doi: 10.1158/1078-0432.CCR-14-2422. Epub 2015 Mar 24.

15.

Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.

Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, Polanski R, Burt DJ, Simpson KL, Morris K, Pepper SD, Nonaka D, Greystoke A, Kelly P, Bola B, Krebs MG, Antonello J, Ayub M, Faulkner S, Priest L, Carter L, Tate C, Miller CJ, Blackhall F, Brady G, Dive C.

Nat Med. 2014 Aug;20(8):897-903. doi: 10.1038/nm.3600. Epub 2014 Jun 1.

PMID:
24880617
16.

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity.

Gibb A, Greystoke A, Ranson M, Linton K, Neeson S, Hampson G, Illidge T, Smith E, Dive C, Pettitt A, Lister A, Johnson P, Radford J.

Br J Cancer. 2013 Nov 12;109(10):2560-5. doi: 10.1038/bjc.2013.605. Epub 2013 Oct 17.

17.

The interaction between prognostic and pharmacodynamic biomarkers.

Bouranis L, Sperrin M, Greystoke A, Dive C, Renehan AG.

Br J Cancer. 2013 Oct 1;109(7):1782-5. doi: 10.1038/bjc.2013.527. Epub 2013 Sep 3.

18.

Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: a short communication.

Greystoke A, Harris G, Jenkins M, Goonetilleke D, Moore D, Lancashire M, Ranson M, Hughes A, Clack G, Dive C.

J Pharm Biomed Anal. 2013 Oct;84:184-8. doi: 10.1016/j.jpba.2013.06.010. Epub 2013 Jun 21.

19.

Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer.

Greystoke A, Dean E, Saunders MP, Cummings J, Hughes A, Ranson M, Dive C, Renehan AG.

Br J Cancer. 2012 Oct 23;107(9):1518-24. doi: 10.1038/bjc.2012.416. Epub 2012 Sep 20.

20.

How many diseases are colorectal cancer?

Greystoke A, Mullamitha SA.

Gastroenterol Res Pract. 2012;2012:564741. Epub 2012 Sep 9.

Supplemental Content

Loading ...
Support Center